[{"id":"633379f3-07d9-4dba-9d28-5db185a69a88","acronym":"NIMBUS","url":"https://clinicaltrials.gov/study/NCT03789110","created_at":"2021-01-18T18:44:16.411Z","updated_at":"2025-02-25T14:27:57.200Z","phase":"Phase 2","brief_title":"NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer","source_id_and_acronym":"NCT03789110 - NIMBUS","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2 • PGR • TMB","pipe":" | ","alterations":" HR positive • HER-2 amplification • HER-2 negative • ER positive + PGR positive • PGR positive","tags":["HER-2 • PGR • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 amplification • HER-2 negative • ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/08/2019","start_date":" 03/08/2019","primary_txt":" Primary completion: 09/30/2021","primary_completion_date":" 09/30/2021","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-08-20"},{"id":"0ee26aec-9472-428d-8a6d-1452f4bd5bae","acronym":"","url":"https://clinicaltrials.gov/study/NCT05283837","created_at":"2022-03-17T12:53:29.116Z","updated_at":"2025-02-25T13:54:17.342Z","phase":"Phase 3","brief_title":"A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)","source_id_and_acronym":"NCT05283837","lead_sponsor":"Zydus Lifesciences Limited","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • ER positive + PGR positive • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Perjeta (pertuzumab)"],"overall_status":"Completed","enrollment":" Enrollment 268","initiation":"Initiation: 09/26/2022","start_date":" 09/26/2022","primary_txt":" Primary completion: 09/06/2023","primary_completion_date":" 09/06/2023","study_txt":" Completion: 09/06/2023","study_completion_date":" 09/06/2023","last_update_posted":"2024-07-18"},{"id":"7400d1d1-c93a-4e3e-a35d-94aa2105cdee","acronym":"","url":"https://clinicaltrials.gov/study/NCT05378464","created_at":"2022-05-18T13:00:43.972Z","updated_at":"2024-07-02T16:34:38.084Z","phase":"Phase 1","brief_title":"Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine \u0026 Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer","source_id_and_acronym":"NCT05378464","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" HER-2 • PGR • CD4","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • ER positive + PGR positive • PGR positive","tags":["HER-2 • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Trazimera (trastuzumab-qyyp) • pepinemab (VX15)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 05/31/2022","start_date":" 05/31/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-06-05"},{"id":"3f558519-49f6-41cf-a5ae-3622a67f25d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04614194","created_at":"2021-01-19T20:33:11.525Z","updated_at":"2024-07-02T16:35:02.537Z","phase":"Phase 2","brief_title":"Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib","source_id_and_acronym":"NCT04614194","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" HER-2 • ER • PGR • CD8","pipe":" | ","alterations":" HER-2 negative • ER positive + PGR positive • PGR positive • CD8 positive","tags":["HER-2 • ER • PGR • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER positive + PGR positive • PGR positive • CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • letrozole"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/15/2021","start_date":" 04/15/2021","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 04/15/2028","study_completion_date":" 04/15/2028","last_update_posted":"2024-05-20"},{"id":"993964d3-1513-41e2-baa4-1d2367679f53","acronym":"","url":"https://clinicaltrials.gov/study/NCT06067503","created_at":"2023-10-05T16:11:02.225Z","updated_at":"2024-07-02T16:35:03.532Z","phase":"Phase 2","brief_title":"Biomarkers to Detect Endocrine Therapy Resistance","source_id_and_acronym":"NCT06067503","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER positive + PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER positive + PGR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 04/30/2024","start_date":" 04/30/2024","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-05-15"},{"id":"6218fa0c-7831-46e9-aa54-e8cf3a80ef2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05675579","created_at":"2023-01-09T15:59:22.277Z","updated_at":"2024-07-02T16:35:04.264Z","phase":"Phase 2","brief_title":"A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)","source_id_and_acronym":"NCT05675579","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • ER positive + PGR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • ER positive + PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 05/23/2023","start_date":" 05/23/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-13"},{"id":"5d8ffb56-1901-4937-a8c8-b205ac4fa2e1","acronym":"INSIGHT","url":"https://clinicaltrials.gov/study/NCT05693766","created_at":"2023-01-23T16:00:10.585Z","updated_at":"2024-07-02T16:35:08.227Z","phase":"Phase 2","brief_title":"Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort","source_id_and_acronym":"NCT05693766 - INSIGHT","lead_sponsor":"Sonya Reid","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • ER positive + PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER positive + PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 09/11/2023","start_date":" 09/11/2023","primary_txt":" Primary completion: 08/31/2027","primary_completion_date":" 08/31/2027","study_txt":" Completion: 08/31/2037","study_completion_date":" 08/31/2037","last_update_posted":"2024-04-23"},{"id":"9a0f0c73-01fd-48ef-ba35-a8f9575df14c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04521764","created_at":"2021-01-18T21:39:40.709Z","updated_at":"2024-07-02T16:35:08.994Z","phase":"Phase 1","brief_title":"A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer","source_id_and_acronym":"NCT04521764","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • PD-L1 • ER • PGR • HMGB1","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • ER positive + PGR positive • PGR positive","tags":["HER-2 • PD-L1 • ER • PGR • HMGB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • ER positive + PGR positive • PGR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 09/23/2020","start_date":" 09/23/2020","primary_txt":" Primary completion: 08/15/2027","primary_completion_date":" 08/15/2027","study_txt":" Completion: 08/15/2027","study_completion_date":" 08/15/2027","last_update_posted":"2024-04-18"},{"id":"a37af355-2625-4415-ae7c-59d702230ad7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02776917","created_at":"2021-01-18T13:37:02.048Z","updated_at":"2024-07-02T16:35:10.661Z","phase":"Phase 1","brief_title":"Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer","source_id_and_acronym":"NCT02776917","lead_sponsor":"Barbara Parker, MD","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • zilovertamab (UC-961)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 08/15/2018","start_date":" 08/15/2018","primary_txt":" Primary completion: 07/13/2021","primary_completion_date":" 07/13/2021","study_txt":" Completion: 02/26/2024","study_completion_date":" 02/26/2024","last_update_posted":"2024-04-10"},{"id":"3ba19f6b-ef31-414d-988d-c03d4cf8bba9","acronym":"SerMa","url":"https://clinicaltrials.gov/study/NCT05899387","created_at":"2023-06-12T15:08:51.409Z","updated_at":"2024-07-02T16:35:11.057Z","phase":"","brief_title":"Seroma of the Mammary Gland","source_id_and_acronym":"NCT05899387 - SerMa","lead_sponsor":"University Hospital Augsburg","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • ER positive + PGR positive • PGR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER positive + PGR positive • PGR positive • PGR negative"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 04/01/2024","start_date":" 04/01/2024","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-04-08"},{"id":"f436621f-778f-4f1e-9c28-9ec0a59dad05","acronym":"COOL-IT","url":"https://clinicaltrials.gov/study/NCT05505643","created_at":"2022-08-18T15:55:55.915Z","updated_at":"2024-07-02T16:35:10.903Z","phase":"","brief_title":"Cryoablation vs Lumpectomy in T1 Breast Cancers","source_id_and_acronym":"NCT05505643 - COOL-IT","lead_sponsor":"Washington University School of Medicine","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • ER positive + PGR positive • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER positive + PGR positive • PGR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 256","initiation":"Initiation: 04/03/2024","start_date":" 04/03/2024","primary_txt":" Primary completion: 10/31/2031","primary_completion_date":" 10/31/2031","study_txt":" Completion: 10/31/2031","study_completion_date":" 10/31/2031","last_update_posted":"2024-04-08"},{"id":"119a635b-e1e4-4994-978a-d639dd45d32e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03612648","created_at":"2021-01-18T17:45:22.274Z","updated_at":"2024-07-02T16:35:13.342Z","phase":"","brief_title":"Three Fraction Accelerated Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-risk Stage 0 and I Breast Carcinoma","source_id_and_acronym":"NCT03612648","lead_sponsor":"Washington University School of Medicine","biomarkers":" PGR","pipe":" | ","alterations":" ER positive + PGR positive • PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive + PGR positive • PGR positive"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 08/30/2018","start_date":" 08/30/2018","primary_txt":" Primary completion: 03/22/2026","primary_completion_date":" 03/22/2026","study_txt":" Completion: 03/22/2026","study_completion_date":" 03/22/2026","last_update_posted":"2024-03-21"},{"id":"2016d7af-e366-49bd-9dcb-d28e26192082","acronym":"LACOG1018","url":"https://clinicaltrials.gov/study/NCT03936270","created_at":"2021-01-18T19:23:09.176Z","updated_at":"2024-07-02T16:35:18.554Z","phase":"Phase 2","brief_title":"Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer","source_id_and_acronym":"NCT03936270 - LACOG1018","lead_sponsor":"Latin American Cooperative Oncology Group","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive + PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive + PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • letrozole"],"overall_status":"Completed","enrollment":" Enrollment 43","initiation":"Initiation: 03/05/2020","start_date":" 03/05/2020","primary_txt":" Primary completion: 01/18/2022","primary_completion_date":" 01/18/2022","study_txt":" Completion: 05/02/2023","study_completion_date":" 05/02/2023","last_update_posted":"2024-02-20"},{"id":"b84fa649-6a21-4a69-88fb-39a7bfebf3aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02422641","created_at":"2021-01-18T11:35:12.764Z","updated_at":"2024-07-02T16:35:19.750Z","phase":"Phase 2","brief_title":"Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis","source_id_and_acronym":"NCT02422641","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate IV"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 05/01/2015","start_date":" 05/01/2015","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2024-02-12"},{"id":"a01b13a9-a81d-4566-9d3e-266d627428f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02738866","created_at":"2021-01-18T13:24:51.951Z","updated_at":"2024-07-02T16:35:21.102Z","phase":"Phase 2","brief_title":"Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor","source_id_and_acronym":"NCT02738866","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" HER-2 • ER • PGR • PI3K","pipe":" | ","alterations":" ER positive • HER-2 negative • ER positive + PGR positive • ESR1 mutation","tags":["HER-2 • ER • PGR • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • ER positive + PGR positive • ESR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • fulvestrant"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/25/2016","start_date":" 10/25/2016","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-02"},{"id":"1ddd1735-bc19-4604-9893-5a36ff15e338","acronym":"","url":"https://clinicaltrials.gov/study/NCT04961632","created_at":"2021-07-14T14:53:27.048Z","updated_at":"2024-07-02T16:35:21.298Z","phase":"Phase 1","brief_title":"Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376","source_id_and_acronym":"NCT04961632","lead_sponsor":"National Cancer Centre, Singapore","biomarkers":" PGR","pipe":" | ","alterations":" ER positive + PGR positive • PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 12/23/2020","start_date":" 12/23/2020","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-02-01"},{"id":"c64ea4cb-7d7e-4b79-9762-01364f918424","acronym":"","url":"https://clinicaltrials.gov/study/NCT05031065","created_at":"2021-09-01T14:53:11.998Z","updated_at":"2024-07-02T16:35:21.931Z","phase":"","brief_title":"Prognostic Indicators for Radiation-induced Breast Fibrosis","source_id_and_acronym":"NCT05031065","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • ER positive + PGR positive • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER positive + PGR positive • PGR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 01/24/2024","start_date":" 01/24/2024","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-29"},{"id":"eeaaa86c-136f-4f91-9901-af1955313aad","acronym":"EMPOWER","url":"https://clinicaltrials.gov/study/NCT04333706","created_at":"2021-01-18T20:59:01.099Z","updated_at":"2024-07-02T16:35:22.962Z","phase":"Phase 1/2","brief_title":"A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)","source_id_and_acronym":"NCT04333706 - EMPOWER","lead_sponsor":"University of Southern California","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • ER positive + PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER positive + PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • Kevzara (sarilumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 09/26/2020","start_date":" 09/26/2020","primary_txt":" Primary completion: 11/03/2025","primary_completion_date":" 11/03/2025","study_txt":" Completion: 11/03/2026","study_completion_date":" 11/03/2026","last_update_posted":"2024-01-18"},{"id":"d706a100-20c3-4942-98f1-dac486c56909","acronym":"ORIENTA","url":"https://clinicaltrials.gov/study/NCT06102824","created_at":"2023-10-26T15:14:20.313Z","updated_at":"2024-07-02T16:35:23.595Z","phase":"Phase 2","brief_title":"Organoid-based Functional Precision Therapy for Advanced Breast Cancer","source_id_and_acronym":"NCT06102824 - ORIENTA","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative • ER positive + PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • ER positive + PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy) • Ixempra (ixabepilone) • Lipusu (liposomal paclitaxel) • utidelone IV (UTD1)"],"overall_status":"Recruiting","enrollment":" Enrollment 252","initiation":"Initiation: 01/20/2024","start_date":" 01/20/2024","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-01-12"},{"id":"6742b9d6-dfa2-4581-845d-9cbd0e43f94e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04273555","created_at":"2021-01-18T20:45:29.700Z","updated_at":"2024-07-02T16:35:25.427Z","phase":"Phase 1/2","brief_title":"Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging","source_id_and_acronym":"NCT04273555","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • ER positive + PGR positive • PGR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive + PGR positive • PGR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2023-12-22"},{"id":"52a92fb6-7f63-4f05-8675-4156e2d78b6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02076074","created_at":"2021-01-18T09:34:02.974Z","updated_at":"2024-07-02T16:35:27.130Z","phase":"","brief_title":"Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer","source_id_and_acronym":"NCT02076074","lead_sponsor":"Washington University School of Medicine","biomarkers":" PGR","pipe":" | ","alterations":" ER positive + PGR positive • PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive + PGR positive • PGR positive"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 04/02/2014","start_date":" 04/02/2014","primary_txt":" Primary completion: 05/18/2023","primary_completion_date":" 05/18/2023","study_txt":" Completion: 05/18/2023","study_completion_date":" 05/18/2023","last_update_posted":"2023-12-05"},{"id":"85f81c0f-5b86-4d0c-8999-6cdd871e6e95","acronym":"REaCT-HER TIME","url":"https://clinicaltrials.gov/study/NCT04928261","created_at":"2021-06-16T18:52:47.498Z","updated_at":"2024-07-02T16:35:27.340Z","phase":"Phase 4","brief_title":"Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy","source_id_and_acronym":"NCT04928261 - REaCT-HER TIME","lead_sponsor":"Ottawa Hospital Research Institute","biomarkers":" PGR","pipe":" | ","alterations":" HER-2 positive • ER positive + PGR positive • PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 12/13/2021","start_date":" 12/13/2021","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2023-12-01"},{"id":"59bdfa97-7b2e-46bf-97c1-23ab33821d5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04081389","created_at":"2021-01-18T19:59:01.001Z","updated_at":"2024-07-02T16:35:37.452Z","phase":"Phase 1","brief_title":"Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer","source_id_and_acronym":"NCT04081389","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PGR","pipe":" | ","alterations":" ER positive + PGR positive • PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin • Intron A (interferon α-2b) • Ampligen (rintatolimod) • celecoxib oral • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 12/06/2019","start_date":" 12/06/2019","primary_txt":" Primary completion: 05/24/2022","primary_completion_date":" 05/24/2022","study_txt":" Completion: 02/27/2023","study_completion_date":" 02/27/2023","last_update_posted":"2023-09-11"},{"id":"8bdfaf12-8486-47c4-a415-ba2a4e2e83f3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00959244","created_at":"2021-01-18T03:44:01.104Z","updated_at":"2024-07-02T16:35:38.273Z","phase":"","brief_title":"Study of Urine Samples From Women With Newly Diagnosed Breast Cancer Enrolled on Clinical Trial UNMC-08105","source_id_and_acronym":"NCT00959244","lead_sponsor":"University of Nebraska","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive + PGR positive • PGR positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive + PGR positive • PGR positive"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 02/02/2009","start_date":" 02/02/2009","primary_txt":" Primary completion: 09/25/2009","primary_completion_date":" 09/25/2009","study_txt":" Completion: 09/25/2009","study_completion_date":" 09/25/2009","last_update_posted":"2023-09-01"}]